Fungal Immunosuppressive Compounds
- Technology Benefits
- No cytotoxicity. More effective immunosupressant.
- Technology Application
- Immunosuppressive drugs for tissue transplantation, various autoimmune diseases and with some other non-autoimmune inflammatory diseases.
- Detailed Technology Description
- Researchers at UCLA have isolated a novel compound from an endophytic fungal microbe in a tropical rainforest that is a more effective immunosupressant and has much lower toxicity compared to existing immunosupressants used in clinical practice. In particular, this novel compound has strong ability to inhibit the production of IL-2 from activated CD4 T cells.
- Supplementary Information
- Patent Number: US8080256B2
Application Number: US2010741804A
Inventor: Strobel, Gary A. | Ren, Yuhao | Teplow, David B.
Priority Date: 9 Nov 2007
Priority Number: US8080256B2
Application Date: 6 May 2010
Publication Date: 20 Dec 2011
IPC Current: A61K003900
US Class: 4242741 | 5140033 | 530300 | 530350 | 530820 | 530823
Assignee Applicant: The Regents of the University of California
Title: Endophytic fungi from Pteromischum sp. plant, compounds and methods of use
Usefulness: Endophytic fungi from Pteromischum sp. plant, compounds and methods of use
Summary: The endophytic fungus is useful for suppressing an immune response; and protecting a plant against a fungal pathogen (all claimed). It is preferably useful for suppressing an immune response associated with an organ or tissue transplantation, autoimmune disease, or a non-autoimmune inflammatory disease, where the autoimmune diseases include rheumatoid arthritis, juvenile oligoarthritis, collagen-induced arthritis, adjuvant-induced arthritis, Sjogren's syndrome, multiple sclerosis, experimental autoimmune encephalomyelitis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), autoimmune gastric atrophy, pemphigus vulgaris, psoriasis, vitiligo, type I diabetes, non-obese diabetes, myasthenia gravis, Grave's disease, Hashimoto's thyroiditis, sclerosing cholangitis, sclerosing sialadenitis, systemic lupus erythematosus, autoimmune thrombocytopenic purpura, Goodpasture's syndrome, Addison's disease, systemic sclerosis, polymyositis, dermatomyositis, autoimmune hemolytic anemia, and pernicious anemia.
Novelty: New endophytic fungus isolated from a Pteromischum sp. plant, where the isolated endophytic fungus has antifungal or immunosuppressive activity, useful for suppressing an immune response and protecting a plant against a fungal pathogen
- Industry
- Biomedical
- Sub Category
- Pathogen
- Application No.
- 8080256
- Others
-
State Of Development
The novel compound has been successfully isolated from the fungus and thorough tests have been done to assure its immunosuppressive activities and its lack of toxicity. Background
Endophytes, microorganisms that reside in the tissues of living plants, are relatively unstudied and potential sources of novel natural products for exploitation in medicine, agriculture, and industry. Endophytic microbes, often in tropical rainforests, make compounds that have potential uses in medicine and agriculture, such as antibiotics, antioxidants and immunosuppressants. A collection of fungal endophytes in the tropical rainforest is of particular interest since it shows strong inhibitory activity toward a common pathogen of many plant species. The compound extracted from the fungal endophyte reveals strong similarities to cyclosporin A, an important immunosupressive drug.
Since the discovery of cyclosporin A in 1976, it has been the principal immunosuppressive agent used in medicine. In present days, in addition to cyclosporin A, tacrolimus and sirolimus also are immunosupressants used in clinical practice and they act on T cell lymphocytes. However, all three drugs produce severe side-effects, including nephrotoxicity, beta-cell toxicity, hypertension and hyperlipidaemia.Tech ID/UC Case
23237/2008-369-0
Related Cases
2008-369-0
- *Abstract
-
UCLA inventors have discovered a novel compound from a fungus that would have broad applicability for the treatment of human autoimmune diseases and transplantation rejection.
- *Applications
-
Immunosuppressive drugs for tissue transplantation, various autoimmune diseases and with some other non-autoimmune inflammatory diseases.
- *IP Issue Date
- Dec 20, 2011
- *Principal Investigator
-
Name: Yuhao Ren
Department:
Name: Gary Strobel
Department:
Name: David Teplow
Department:
- Country/Region
- USA
